Malignant Transformation of Osteochondroma: A Case of Secondary Peripheral Chondrosarcoma
Key Takeaway
Malignant transformation of an osteochondroma to a peripheral chondrosarcoma is suspected with new onset pain, rapid growth of a previously stable mass, or neurological symptoms. Diagnosis relies on MRI showing a cartilaginous cap exceeding 2 cm in adults, irregular calcifications, and signs of soft tissue invasion or marrow edema. Clinical history and imaging are crucial.
A 48-year-old male presents with an 8-month history of worsening left proximal leg pain and a palpable mass. He has a known "lump" there since childhood that was previously asymptomatic. He now has mild numbness in the superficial peroneal nerve distribution. Please describe your initial assessment and the radiographic findings presented in this image.
Candidate: This patient has a likely secondary chondrosarcoma arising from a pre-existing osteochondroma. The radiograph shows a broad-based bony lesion on the proximal tibia. It has cortical and medullary continuity. However, there is irregular calcification in the soft tissue cap and cortical indistinctness, which are concerning for malignancy. I would perform an MRI to assess the cartilage cap thickness.
Failing to emphasize the "red flags" (new pain in a skeletally mature adult) or failing to acknowledge the critical diagnostic threshold for the cartilaginous cap thickness on MRI. Candidates often describe the lesion but fail to mention the urgency of biopsy planning relative to the excision plan.
The candidate should immediately identify this as a "malignant transformation of a hereditary or sporadic osteochondroma." Key points: 1. Highlight the clinical history: Adult with new pain/growth is the hallmark of secondary chondrosarcoma. 2. Radiological features: Mention cortical/medullary continuity, but point out the "popcorn" calcifications and cortical breakthrough. 3. Immediate step: Mandate an MRI to measure the cartilaginous cap—a thickness >1.5-2.0cm in an adult is the diagnostic buzzword for malignant degeneration. 4. State the importance of biopsy planning (biopsy the cap, not the stalk) to ensure the tract is included in definitive wide resection.
You decide to biopsy this lesion. What are the critical oncological principles regarding the biopsy of a suspected peripheral chondrosarcoma?
Candidate: I would perform an image-guided core needle biopsy. The most important thing is to biopsy the cartilaginous cap, not the bony stalk, because the stalk will only show benign bone. The biopsy tract must be placed so that it can be completely excised during the final surgery.
Forgetting to mention the specific placement of the biopsy incision. Failing to consult the operating surgeon prior to the biopsy is a critical error in oncological management.
The answer must be structured: 1. Location: Target the thickest, non-calcified portion of the cartilage cap; the stalk is diagnostic of the underlying osteochondroma, not the transformation. 2. Planning: The biopsy path must be marked and positioned such that the entire tract is easily resectable en bloc during the definitive wide excision. 3. Multidisciplinary: Perform the biopsy in coordination with the surgeon who will perform the definitive resection to avoid seeding soft tissues that cannot be easily excised later.
During the surgical resection, you are preparing to use a tourniquet. Are there any specific oncological contraindications regarding its use?
Candidate: Yes. I would use a tourniquet for a bloodless field, but I would not use an Esmarch bandage to exsanguinate the limb because that could mechanically push tumor cells into the systemic circulation. I would exsanguinate by elevation only.
Suggesting an Esmarch bandage is acceptable, or forgetting the exsanguination step entirely. This demonstrates a lack of basic oncological safety knowledge.
The candidate must explicitly state: "Exsanguination via Esmarch bandage is contraindicated due to the risk of mechanical tumor embolization." The correct technique is to exsanguinate by elevation for 3-5 minutes, then inflate the tourniquet. This demonstrates high-level safety awareness for malignant bone tumor surgery.
